22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › BIOCRYST PHARMACEUTICALS INC. › 2024-2025

BIOCRYST PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and BIOCRYST PHARMACEUTICALS INC.’s Form 8-K, filed June 16, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 265Asset managers, any item
  • 1,300Fund votes
  • June 12, 2025Meeting date

Results at a glance

Meeting of June 12, 2025: 5 items on BIOCRYST PHARMACEUTICALS INC.’s Form 8-K, filed June 16, 2025: 2 elected · 3 approved.

Dissent

Significant dissent: 1 equity or compensation plan (26.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BIOCRYST PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by BIOCRYST PHARMACEUTICALS INC.

These tallies are BIOCRYST PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BIOCRYST PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 12, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Steven K. Galson, M.D., MPH 146,067,707---- 3,688,084-- 98%Elected—
Elect Director: Alan G. Levin 146,065,836---- 3,689,955-- 98%Elected—
The proposed ratification of the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2025 174,697,8923,838,292492,505 ---- 98%Approved—
The proposed non-binding, advisory resolution regarding executive compensation 143,096,0946,357,577302,120 --29,272,898 96%Approved—
The Incentive Plan Proposal 110,230,30638,875,495649,990 --29,272,898 74%Approved—

Source: BIOCRYST PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 16, 2025 — read the filing on EDGAR.

How asset managers voted at the BIOCRYST PHARMACEUTICALS INC. 2024-2025 meeting

265 asset managers disclosed a vote on at least one BIOCRYST PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Steven K. Galson, M.D., MPH

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 146,067,707WITHHELD: 3,688,084
Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: Election of Directors (each to serve until the 2028 Annual Meeting of Stockholders): Steven Galson, M.D., MPH

BIOCRYST PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Steven K. Galson, M.D., MPH”): 146,067,707 for, 3,688,084 withheld, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The nominees for director were elected by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 66 asset managers voting on “Election of Directors (each to serve until the 2028 Annual Meeting of Stockholders): Steven Galson, M.D., MPH” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard21,170,4560 00For
BlackRock11,197,8030 00For
Fidelity5,530,9270 00For
ACAP Strategic Fund3,546,5400 00For
TIAA3,538,6600 00For
State Street3,244,1380 00For
Charles Schwab1,949,0720 00For
Columbia Threadneedle1,456,8950 00For
Advantage Advisers Xanthus Fund, L.L.C.1,036,4080 00For
Invesco839,7920 00For
First Trust650,1650 00For
Equitable328,6520 0273,370Mixed
AMG FUNDS529,3170 00For
John Hancock464,4070 00For
Voya382,4580 00For
HUSSMAN INVESTMENT TRUST357,0000 00For
Exchange Place Advisors Trust356,5860 00For
QUANTITATIVE MASTER SERIES LLC353,5400 00For
Segall Bryant & Hamill Trust309,5220 00For
Lincoln Financial286,4480 00For
CLEARWATER INVESTMENT TRUST266,3860 00For
Goldman Sachs250,7990 00For
Federated Hermes182,4250 00For
ALPS ETF Trust152,9850 00For
American Century137,0970 00For

Fund voting reports, all 66 managers: 60,159,359 for, 344,719 withheld, 0 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “Election of Directors (each to serve until the 2028 Annual Meeting of Stockholders): Steven Galson, M.D., MPH” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RP Management, LLC3,846,1540 00For

Institutional-manager reports, all 1 managers: 3,846,154 for.

Elect Director: Alan G. Levin

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 7 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 146,065,836WITHHELD: 3,689,955
Details: description as filed, official tally, votes by 66 asset managers

Description as filed by funds: Election of Directors (each to serve until the 2028 Annual Meeting of Stockholders): Alan Levin

BIOCRYST PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Alan G. Levin”): 146,065,836 for, 3,689,955 withheld, per its Form 8-K filed June 16, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The nominees for director were elected by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 65 asset managers voting on “Election of Directors (each to serve until the 2028 Annual Meeting of Stockholders): Alan Levin” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard21,170,4560 00For
BlackRock11,197,8030 00For
Fidelity5,530,9270 00For
ACAP Strategic Fund3,546,5400 00For
TIAA3,538,6600 00For
State Street3,244,1380 00For
Charles Schwab1,949,0720 00For
Columbia Threadneedle1,456,8950 00For
Advantage Advisers Xanthus Fund, L.L.C.1,036,4080 00For
Invesco839,7920 00For
First Trust650,1650 00For
Equitable328,6520 0273,370Mixed
AMG FUNDS529,3170 00For
John Hancock464,4070 00For
Voya382,4580 00For
Exchange Place Advisors Trust356,5860 00For
QUANTITATIVE MASTER SERIES LLC353,5400 00For
Segall Bryant & Hamill Trust309,5220 00For
Lincoln Financial286,4480 00For
CLEARWATER INVESTMENT TRUST266,3860 00For
Goldman Sachs250,7990 00For
Federated Hermes182,4250 00For
ALPS ETF Trust152,9850 00For
American Century137,0970 00For
Direxion Shares ETF Trust134,1050 00For

Fund voting reports, all 65 managers: 59,802,359 for, 344,719 withheld, 0 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “Election of Directors (each to serve until the 2028 Annual Meeting of Stockholders): Alan Levin” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RP Management, LLC3,846,1540 00For

Institutional-manager reports, all 1 managers: 3,846,154 for.

The Incentive Plan Proposal

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

74% Approved · of votes cast

FOR 74%AGAINST
FOR: 110,230,306AGAINST: 38,875,495
Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: TO APPROVE AN AMENDED AND RESTATED STOCK INCENTIVE PLAN, INCREASING THE NUMBER OF SHARES AVAILABLE FOR ISSUANCE UNDER THE STOCK INCENTIVE PLAN.

BIOCRYST PHARMACEUTICALS INC.’s own tally for this item (“The Incentive Plan Proposal was approved by the following votes:”): 110,230,306 for, 38,875,495 against — passed, per its Form 8-K filed June 16, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Incentive Plan Proposal was approved by the following votes:”
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 65 asset managers voting on “TO APPROVE AN AMENDED AND RESTATED STOCK INCENTIVE PLAN, INCREASING THE NUMBER OF SHARES AVAILABLE FOR ISSUANC” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard21,039,956130,500 00For
BlackRock11,197,8030 00For
Fidelity4,825,802705,125 00Mixed
ACAP Strategic Fund3,546,5400 00For
TIAA03,538,660 00Against
State Street3,240,1184,020 00For
Charles Schwab1,949,0720 00For
Columbia Threadneedle1,456,8950 00For
Advantage Advisers Xanthus Fund, L.L.C.1,036,4080 00For
Invesco0839,792 00Against
First Trust0650,165 00Against
Equitable328,652273,370 00Mixed
AMG FUNDS0529,317 00Against
John Hancock0464,407 00Against
Voya0382,458 00Against
HUSSMAN INVESTMENT TRUST0357,000 00Against
Exchange Place Advisors Trust356,5860 00For
QUANTITATIVE MASTER SERIES LLC353,5400 00For
Segall Bryant & Hamill Trust0309,522 00Against
Lincoln Financial152,503133,945 00Mixed
CLEARWATER INVESTMENT TRUST87,221179,165 00Mixed
Goldman Sachs0250,799 00Against
Federated Hermes182,4250 00For
ALPS ETF Trust0152,985 00Against
American Century0137,097 00Against

Fund voting reports, all 65 managers: 50,425,977 for, 10,027,610 against, 50,417 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “TO APPROVE AN AMENDED AND RESTATED STOCK INCENTIVE PLAN, INCREASING THE NUMBER OF SHARES AVAILABLE FOR ISSUANC” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RP Management, LLC3,846,1540 00For

Institutional-manager reports, all 1 managers: 3,846,154 for.

The proposed non-binding, advisory resolution regarding executive compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 143,096,094AGAINST: 6,357,577

Prior year: 95.6% for (May 15, 2024 meeting) ▲ 0.2 pts

Details: description as filed, official tally, votes by 260 asset managers

Description as filed by funds: To hold a non-binding, advisory vote regarding executive compensation.

BIOCRYST PHARMACEUTICALS INC.’s own tally for this item (“The proposed non-binding, advisory resolution regarding executive compensation was approved by the following votes:”): 143,096,094 for, 6,357,577 against — passed, per its Form 8-K filed June 16, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposed non-binding, advisory resolution regarding executive compensation was approved by the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of BIOCRYST PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (6 managers, 2,677,282 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 65 asset managers voting on “To hold a non-binding, advisory vote regarding executive compensation.” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard21,170,4560 00For
BlackRock11,197,8030 00For
Fidelity5,530,9270 00For
ACAP Strategic Fund3,546,5400 00For
TIAA3,538,6600 00For
State Street3,244,1380 00For
Charles Schwab1,949,0720 00For
Columbia Threadneedle1,456,8950 00For
Advantage Advisers Xanthus Fund, L.L.C.1,036,4080 00For
Invesco0839,792 00Against
First Trust650,1650 00For
Equitable602,0220 00For
AMG FUNDS529,3170 00For
John Hancock464,4070 00For
Voya382,4580 00For
HUSSMAN INVESTMENT TRUST0357,000 00Against
Exchange Place Advisors Trust356,5860 00For
QUANTITATIVE MASTER SERIES LLC353,5400 00For
Segall Bryant & Hamill Trust309,5220 00For
Lincoln Financial286,4480 00For
CLEARWATER INVESTMENT TRUST266,3860 00For
Goldman Sachs250,7990 00For
Federated Hermes182,4250 00For
ALPS ETF Trust152,9850 00For
American Century0137,097 00Against

Fund voting reports, all 65 managers: 59,103,549 for, 1,350,038 against, 50,417 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 214 asset managers voting on “To hold a non-binding, advisory vote regarding executive compensation.” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock9,478,7350 00For
Avoro Capital Advisors LLC7,568,4940 00For
State Street7,298,3730 00For
DEERFIELD MANAGEMENT COMPANY, L.P.5,634,0660 00For
GEODE CAPITAL MANAGEMENT, LLC4,996,1390 00For
RP Management, LLC3,846,1540 00For
Nuveen3,559,0050 00For
ALKEON CAPITAL MANAGEMENT LLC2,789,0860 00For
Fisher Asset Management, LLC2,690,5790 00For
GW&K Investment Management, LLC50,1500 00For
JUPITER ASSET MANAGEMENT LTD2,345,7470 00For
Caligan Partners LP2,332,7090 00For
Two Sigma2,041,7120 00For
Charles Schwab1,949,6150 00For
1919 Investment Counsel, LLC1,831,3670 00For
Northern Trust1,657,2590 00For
RICE HALL JAMES & ASSOCIATES, LLC1,580,4260 00For
DE Shaw1,458,4500 00For
Invesco0957,245 00Against
Vanguard944,0220 00For
Legal & General Investment Management Ltd0939,716 00Against
MELLON INVESTMENTS Corp787,3020 00For
SEGALL BRYANT & HAMILL, LLC726,9330 00For
Connor, Clark & Lunn Investment Management Ltd.600,3150 00For
PICTET ASSET MANAGEMENT SA585,2280 00For

Institutional-manager reports, all 214 managers: 78,217,749 for, 2,874,121 against, 1,498 not voted, 2,338,592 mixed, 1,500 unknown. Showing the 25 largest; every one is in the interactive database (link above).

The proposed ratification of the selection of Ernst & Young LLP as the Company's independent registered public…

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 174,697,892AGAINST: 3,838,292

Prior year: 97.7% for (May 15, 2024 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 67 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR 2025.

BIOCRYST PHARMACEUTICALS INC.’s own tally for this item (“The proposed ratification of the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2025 was approved by the following votes:”): 174,697,892 for, 3,838,292 against — passed, per its Form 8-K filed June 16, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposed ratification of the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2025 was approved by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 66 asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR 20” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard21,168,7101,746 00For
BlackRock11,197,8030 00For
Fidelity5,530,9270 00For
ACAP Strategic Fund3,546,5400 00For
TIAA3,538,6600 00For
State Street3,243,980158 00For
Charles Schwab1,949,0720 00For
Columbia Threadneedle1,456,8950 00For
Advantage Advisers Xanthus Fund, L.L.C.1,036,4080 00For
Invesco839,7920 00For
First Trust650,1650 00For
Equitable602,0220 00For
AMG FUNDS529,3170 00For
John Hancock464,4070 00For
Voya382,4580 00For
HUSSMAN INVESTMENT TRUST357,0000 00For
Exchange Place Advisors Trust356,5860 00For
QUANTITATIVE MASTER SERIES LLC353,5400 00For
Segall Bryant & Hamill Trust309,5220 00For
Lincoln Financial286,4480 00For
CLEARWATER INVESTMENT TRUST266,3860 00For
Goldman Sachs250,7990 00For
Federated Hermes182,4250 00For
ALPS ETF Trust152,9850 00For
American Century137,0970 00For

Fund voting reports, all 66 managers: 60,434,568 for, 19,093 against, 50,417 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS FOR 20” at BIOCRYST PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RP Management, LLC3,846,1540 00For

Institutional-manager reports, all 1 managers: 3,846,154 for.

Largest BIOCRYST PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 209,208,000 shares outstanding at the time of that meeting.

Fund voting reports: top BIOCRYST PHARMACEUTICALS INC. shareholders by shares voted on “Election of Directors (each to serve until the 2028 Annual Meeting of Stockholders): Steven…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 10.12%
2BlackRock 5.35%
3Fidelity 2.64%
4ACAP Strategic Fund 1.70%
5TIAA 1.69%
6State Street 1.55%
7Charles Schwab 0.93%
8Columbia Threadneedle 0.70%
9Advantage Advisers Xanthus Fund, L.L.C. 0.50%
10Invesco 0.40%
Institutional-manager reports: top BIOCRYST PHARMACEUTICALS INC. shareholders by shares voted on “To hold a non-binding, advisory vote regarding executive compensation.”, 2024-2025
#Asset manager % of shares outstanding
1BlackRock 4.53%
2Avoro Capital Advisors LLC 3.62%
3State Street 3.49%
4DEERFIELD MANAGEMENT COMPANY, L.P. 2.69%
5GEODE CAPITAL MANAGEMENT, LLC 2.39%
6RP Management, LLC 1.84%
7Nuveen 1.70%
8ALKEON CAPITAL MANAGEMENT LLC 1.33%
9Fisher Asset Management, LLC 1.29%
10GW&K Investment Management, LLC 1.14%

Reported BIOCRYST PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

BIOCRYST PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Vanguard Group46,269,471 —Form 13F, quarter ended March 31, 2025
BlackRock35,680,066 —Form 13F, quarter ended March 31, 2025
JPMorgan Chase19,745,039 —Form 13F, quarter ended March 31, 2025
T. Rowe Price19,198,593 —Form 13F, quarter ended March 31, 2025
FMR (Fidelity)17,966,693 —Form 13F, quarter ended March 31, 2025
State Street16,274,939 —Form 13F, quarter ended March 31, 2025
RA Capital Management, L.P.15,302,186 —Schedule 13G, filed November 12, 2025
Deerfield Mgmt, L.P.14,341,000 —Schedule 13G, filed February 12, 2026
Avoro Capital Advisors LLC13,050,000 —Proxy statement (DEF 14A), proxy filed April 24, 2025
Franklin Templeton12,723,026 —Form 13F, quarter ended March 31, 2025

Percentages above are of 209,208,000 shares outstanding, as reported by BIOCRYST PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At BIOCRYST PHARMACEUTICALS INC.'s shareholder meeting held June 12, 2025, in the 2024-2025 proxy season, 265 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,300 separate fund positions. On the most widely held item on that ballot — To hold a non-binding, advisory vote regarding executive compensation. — BIOCRYST PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BIOCRYST PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BIOCRYST PHARMACEUTICALS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

BIOCRYST PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “BIOCRYST PHARMACEUTICALS (BCRX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/biocryst-pharmaceuticals-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.